A Phase I Open-label, Multi-center Dose-escalation Study to Determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Open-label, Multi-center Dose-escalation Study to Determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Gimatecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 30 Apr 2012 Actual patient number is 120 according to ClinicalTrials.gov.
    • 30 Apr 2012 Actual patient number is 120 according to ClinicalTrials.gov.
    • 30 Apr 2012 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top